50 MG ClomipheneCitrate Tablets IP

50 MG ClomipheneCitrate Tablets IP Specification

Packaging Type
Blister pack

Indication
Anovulatory or oligo-ovulatory infertility

Shelf Life
24 months

Medicine Type
Fine Chemical Drug

Physical Form
Tablets

Ingredients
Chemicals

Treatments & Functions
Used to induce ovulation in women with ovulatory dysfunction

Recommended For
Female infertility treatment

Quantity/Volume
Each box contains 10 strips of 10 tablets each (total 100 tablets)

Storage Instructions
Dry Place

Dose/Strength(Eg : 1mg Or 1 Ml )
50 mg per tablet

Drug Class
Selective Estrogen Receptor Modulator (SERM)

Usage
As directed by the physician

Batch Number
As coded on pack

Prescription Required
Yes

Color
White to off-white

Side Effects
Possible side effects include headache, abdominal discomfort, and visual disturbances

Mfg. & Exp. Date
Printed on each strip or box

Route of Administration
Oral

Warning
Not for use in pregnancy, contraindicated in patients with liver disease or abnormal uterine bleeding

Regulatory Status
Schedule H Prescription Drug

Shape
Round

50 MG ClomipheneCitrate Tablets IP Trade Information

Minimum Order Quantity
10 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
7 Days

Main Export Market(s)
Asia, Australia, North America, Eastern Europe, Western Europe

Main Domestic Market
All India

About 50 MG ClomipheneCitrate Tablets IP

This contains the active ingredient clomiphenecitrate, which is a selective estrogen receptor modulator (SERM). It works by blocking estrogen receptors in the hypothalamus, a part of the brain that regulates the production of hormones involved in ovulation. This is commonly prescribed to women who have difficulty ovulating or irregular menstrual cycles, which can impair fertility. This medication is primarily used to treat infertility in women caused by ovulatory dysfunction, particularly in those with polycystic ovary syndrome (PCOS). 50 MG ClomipheneCitrate Tablets IP is effective in inducing ovulation in the majority of women with ovulatory dysfunction.